Los Angeles residents vote Cedars-Sinai No. 1 for the quality of care and staff

 

Newswise - LOS Angeles (October 22, 2013) - for 18 years in a row, Cedars-Sinai has won a national award from consumption to provide the medical care of high quality and staff in the Los Angeles region based on a survey of households in the area.


Cedars-Sinai has received an award of the 2013-14 National Research Corporation consumer choice. It is only medical center in the Los Angeles area to win the prize to the best professional quality of health in general, image, reputation, doctors and nurses.


"Cedars-Sinai is gratified by this important recognition of our community," said Thomas M. Priselac, President and Chief Executive Officer. "It reflects our commitment to providing compassionate, high quality care for residents in the region."


More than 270,000 households were contacted across the country for the study of knowledge about market research Corporation. Consumers in local markets were asked to which hospitals preferred based on service and quality of care.
Cedars-Sinai is one of only 37 hospitals throughout the country which won, or shared, in their local markets every year since its inception in 1996.


The award is the latest recognition of the commitment of Cedars-Sinai's quality of care.


Earlier this year, the Centers for Medicare & Medicaid Services released data showing that Cedars-Sinai is the only hospital in California (and one of only five in the nation) that have a mortality rate 30 days best that the national rate for five consecutive years in the following major categories of disease: heart failurepneumonia and the acute myocardial infarction (heart attack).


The distinction is significant for Cedars-Sinai treats many patients with advanced heart disease requiring complex interventions, including heart transplants. The programme has made adult heart transplant more than any other medical center in the nation for three consecutive years.


"We are proud of our history of quality," said Michael Langberg, MD, senior Vice President of Medical Affairs and Chief Medical Officer. "It is the result of our personnel, paying special attention to even the smallest detail when it comes to patient care".


# # #



Large, Prospective Study Finds Long-Term Obesity Is Associated with Poorer Pancreatic Cancer Survival

AppId is over the quota
AppId is over the quota

In this News Digest:

- Summary of a study being published online October 21, 2013 in the Journal of Clinical Oncology, reporting that patients with pancreatic cancer who were overweight or obese years before their diagnosis tend to have more advanced disease at diagnosis and shorter survival.

- The findings add to increasing evidence linking obesity with cancer, suggesting that maintaining a healthy body weight not only reduces the risk of developing certain cancers, but may also improve outcomes after a cancer diagnosis.

- Quote for attribution to Smitha Krishnamurthi, MD, American Society of Clinical Oncology Cancer Communications Committee member and gastrointestinal cancers expert

Newswise — New results from a prospective study published in the Journal of Clinical Oncology show that patients with a body mass index (BMI) in the obese range live on average two to three months less after a pancreatic cancer diagnosis, compared with healthy weight patients, even after adjusting for factors that are known to predict survival for patients with this disease, such as age and disease stage. This association was statistically strongest for people who were overweight two decades before their diagnosis.

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. Most patients with pancreatic adenocarcinoma, which accounts for more than 90% of new cases, survive less than a year after their diagnosis.

Obesity is a major public health problem in the United States and many other countries around the world. While it is well known that obesity is a risk factor for heart disease and diabetes, it is becoming increasingly clear that it is also associated with cancer risk and outcomes. In fact, scientists predict that obesity will become the leading preventable cause of cancer in the near future.

Several prior studies have shown that elevated BMI increases the risk of developing pancreatic cancer, but thus far there has been little research on whether BMI affects the aggressiveness of the disease or survival after diagnosis.

“This study adds to mounting evidence for the role of weight control in improving outcomes for patients with cancer. It also reinforces the importance of maintaining a healthy weight throughout your life, which may lead to better outcomes after diagnosis and help prevent pancreatic cancer from developing,” said senior study author Brian M. Wolpin, MD, MPH, an assistant professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA. “While our findings will not affect the way we treat patients today, they provide new leads for investigating the molecular pathways that may be responsible for the survival difference between obese and healthy-weight patients. Hopefully, in the future, that research will bring new approaches for treatment of pancreatic cancer.”

Researchers evaluated the association between patients’ BMI in 1986 and survival after diagnosis of pancreatic cancer among participants from two large prospective cohort studies – the Nurses’ Health Study and the Health Professionals Follow-Up Study. Participants of those studies were surveyed on medical history, health behaviors, and lifestyle choices. The present study assessed 902 cases of pancreatic adenocarcinoma that were diagnosed during a 24-year period.

Overall, the median length of survival after diagnosis for those patients was five months. According to Dr. Wolpin, on average, healthy weight patients (BMI less than 25 kg/m2) lived 2 to 3 months longer than obese patients (BMI greater than or equal to 35 kg/m2). The association between higher prediagnostic BMI and shorter survival persisted after adjusting for differences in age, gender, race/ethnicity, smoking status, and disease stage. Obese patients were also more likely to be diagnosed with advanced disease – 72% of obese patients had metastatic disease at diagnosis compared to 59% of healthy-weight patients.

The association between BMI and survival was even stronger among the 202 patients with high BMI assessed 18-20 years before diagnosis. Assuming that most people remain overweight once they gain weight, according to Dr. Wolpin, this finding suggests that being overweight for a prolonged period of time leads to worse outcomes. This study also suggests further avenues of research on the link between obesity and cancer. For example, it is not yet clear if the same changes that promote tumor development in obese people also affect the aggressiveness of the tumor. Several ongoing studies are already exploring metabolic (energy and nutrient processing) pathways and genomic changes in relation to obesity and cancer. This work might reveal whether tumors that develop in obese people are susceptible to different treatments than tumors that develop in healthy-weight people.

This research was funded in part by a 2009 Conquer Cancer Foundation of ASCO Career Development Award to Brian Wolpin.

ASCO Perspective:
Smitha Krishnamurthi, MD, ASCO Cancer Communications Committee member and gastrointestinal cancers expert
“While previous retrospective studies suggested a link between obesity and pancreatic cancer survival, the prospective nature of this study makes the findings more reliable. An interesting aspect of this study is that it suggests that obesity, particularly chronic obesity, increases the risk of death from pancreatic cancer. This study, however, could not distinguish if the increased risk of death was due to metabolic and inflammatory changes that accompany obesity or due to other health complications of obesity.”

The full study can be found online at the Journal of Clinical Oncology.

About the Journal of Clinical Oncology:
Journal of Clinical Oncology, the flagship journal of the American Society of Clinical Oncology, is a leader in reach, readership, impact, and influence. With a focus on significant clinical oncology research, Journal of Clinical Oncology publishes over 1,000 articles in 36 issues a year.

About ASCO:
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.cancer.net.

###



Dr. Francis O. Walker Welcomed as New President of AANEM

AppId is over the quota
AppId is over the quota

Newswise — The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) is pleased to announce the selection of Francis O. Walker, MD, to lead the organization in 2013-14 as its new president.

Dr. Walker is a professor of neurology at Wake Forest University School of Medicine in Winston Salem, NC. He attended medical school at Indiana University School of Medicine and graduated in 1978. He completed an internal medicine internship, a neurology residency, and a fellowship at University of Iowa Hospitals and Clinics. He completed another fellowship at the University of Michigan Medical Center in 1983. Dr. Walker is certified by the American Board of Electrodiagnostic Medicine and the American Board of Psychiatry & Neurology. He has lectured extensively on the topic of neuromuscular ultrasound and is considered a national expert in this field.

A member of AANEM since 1985, Dr. Walker has served on numerous committees including the Annual Meeting Coordination, CME Advisory, Ultrasound Committees and the Muscle & Nerve Editorial Board. He served on the AANEM Board of Directors and the Finance Committee as President elect and was Chair of the American Board of Electrodiagnostic Medicine (ABEM) Examination Committee from 1999-2006. As president, he will lead the Board of Directors, which has responsibility for the association's strategic planning, policy creation, and financial oversight.

“I look forward to being able to serve this great organization in this capacity,” said Dr. Walker. “The field of medicine is ever changing and the AANEM has always done an admirable job in educating and advocating for its members so that they can better adapt to these changes. In addition to maintaining these traditions, I hope to bring a particular enthusiasm for finding, developing, and applying new technology for the care of our patients with muscle and nerve diseases.”

AANEM Executive Director Shirlyn Adkins added, “Dr. Walker throughout his career has been interested in combining electrodiagnostic studies and ultrasound to improve diagnostic accuracy. As AANEM President, he will continue to improve AANEM’s education and advocacy efforts in this area and the staff and I look forward to working with him during the coming year."

Dr. Walker replaces Peter A. Grant, MD, of Medford, OR, who completed his term on October 18, 2013.

About AANEM
Founded in 1953, the AANEM is a nonprofit membership association dedicated to the advancement of neuromuscular and electrodiagnostic medicine. Nearly 5000 physician members—primarily neurologists and physiatrists—are now joined by allied health professionals and PhD researchers working to improve the quality of medical care provided to patients with muscle and nerve disorders. AANEM programs are guided by its five pillars: education, professional standards, advocacy, communications, and research. Its administrative office is located in Rochester, MN.



Two UC San Diego researchers elected to Institute of medicine

 

Newswise - University of California, San Diego medical school researcher the researchers Joseph G. Gleeson, MD, Howard Hughes Medical Institute and Professor of neuroscience and Pediatrics and Richard D. Kolodner, PhD, Professor of medicine and Ludwig Cancer Research scientist, have been appointed new members of the Institute of Medicine (IOM), considered among the highest honors in the fields of health and medicine.


Gleeson and Kolodner were among 70 new members and 10 foreign partners announced today the IOM annual meeting, bringing the total membership of the IOM to 1966 worldwide. Forty-six members of the Faculty of UC San Diego, current and Emeritus, are members of the IOM.


Joseph Gleeson


Gleeson is the principal investigator at the Center for the development of the brain, a laboratory that seeks to understand the genetic basis of diseases of the brain such as mental retardation, epilepsy and autism using genetic tools. He is also director of the UC San Diego neuroscience Core, Co-Director of the master of Biomedical Sciences and a member of the Institute of genomic medicine at UC San Diego.


He is also a member of the Child Neurology society, the society for Neuroscience and the American Society of human genetics and has served on the editorial boards of the Journal of Child Neurology, Journal of Pediatric Neurology and human Molecular Genetics.


Gleeson got his Bachelor's degree in chemistry from UC San Diego and his title of doctor at the University of Chicago Pritzker School of Medicine. He came to UC San Diego in 1999. His awards and recognition include award Klingenstein Fellowship in neuroscience, a Searle Scholar Award and the Burroughs Wellcome Fund Clinical Scientist Award in translational research.


Richard Kolodner


Kolodner, Professor in cellular and molecular medicine of the Faculty of medicine at UC San Diego and UC San Diego Moores Cancer Center, has made seminal contributions to understanding the connection between cancer and the repair of the DNA mismatch - the ability of cells to correct the genetic DNA.


It is member of the National Academy of Sciences (2000), the Academy American of Arts & Sciences (2008), the American Society of Microbiology, the Genetics Society of America and American Association for Cancer Research. He has served on numerous boards advice and review, including the Board of scientific advisors of the national cancer Institute and Howard Hughes Medical Institute criticizes Scientific Council.


Among his awards are the research award of Dana-Farber Cancer Institute Morse, the Prix Charles S. Mott of the General Motors Cancer Research Foundation and the Landon-AACR Prize for basic cancer research.


Kolodner received his titles of Bachelor's degree and doctorate in biological sciences from UC Irvine and he worked at the medical school of Harvard to the UC San Diego in 1997.


About the Institute of medicine
Founded in 1970 by the National Academy of Sciences, the IOM serves as an independent, science-based, authoritative advisory group to the federal Government of the United States on various topics ranging from the effects on the health of the intake of salt, cancer care and abuse of minors in the armed forces mental illness and gun violence.


###



Loyola University Chicago Professor Named American Academy of Nursing Fellow

AppId is over the quota
AppId is over the quota

Newswise — MAYWOOD, Ill. – Sue Penckofer, PhD, RN, was inducted as a fellow into the American Academy of Nursing on Oct. 19, 2013. This event took place at the Academy’s 40th Annual Meeting in Washington, DC. Dr. Penckofer is a professor at Loyola University Chicago Marcella Niehoff School of Nursing (MNSON).

“I am honored to join this esteemed group,” Dr. Penckofer said. “I look forward to working with my colleagues to advance the profession of nursing and improve health care nationwide.”

Selection for membership in the academy is one of the most prestigious honors in the field of nursing. The academy fellows represent the top nurse researchers, policymakers, scholars, executives, educators and practitioners. This new class of fellows represents all 50 states, the District of Columbia and 19 countries. Dr. Penckofer was among 172 fellows inducted in to the academy. She was named a fellow for her contributions to the field of nursing for her work in improving women’s cardiovascular health, particularly for women afflicted with diabetes who are at greatest risk for cardiac morbidity and mortality.

The academy is composed of more than 2,000 nurse leaders in education, management, practice, policy and research. Selection criteria include evidence of significant contributions to nursing and health care and sponsorship by two current academy fellows. Applicants are reviewed by a panel of elected and appointed fellows, and selection is based, in part, on the extent to which nominees’ nursing careers influence health policies and well-being.

Dr. Sue Penckofer earned her Bachelor of Science and Master of Science in nursing and her doctorate from the University of Illinois at Chicago. She has been an educator and researcher for more than 30 years and is recognized nationally and internationally for her expertise in women’s cardiovascular health, depression, diabetes and vitamin D deficiency. Dr. Penckofer’s research on how emotions can affect overall health and quality of life has helped to transform the care delivered to women with diabetes. She also has made substantive contributions to promoting awareness and understanding of key health issues, which disproportionately affect women in minority and underserved populations.

###

The Loyola University Chicago Health Sciences Division (HSD) advances interprofessional, multidisciplinary and transformative education and research while promoting service to others through stewardship of scientific knowledge and preparation of tomorrow's leaders. The HSD is located on the Health Sciences Campus in Maywood, Illinois. It includes the Marcella Niehoff School of Nursing, the Stritch School of Medicine, the biomedical research programs of the Graduate School, and several other institutes and centers encouraging new research and interprofessional education opportunities across all of Loyola University Chicago. The faculty and staff of the HSD bring a wealth of knowledge, experience, and a strong commitment to seeing that Loyola's health sciences continue to excel and exceed the standard for academic and research excellence. For more on the HSD, visit LUC.edu/hsd.



No Known Hominin Is Ancestor of Neanderthals and Modern Humans

AppId is over the quota
AppId is over the quota

**Photos of the researcher will be available Monday, Oct. 21 at 12 p.m. Eastern.**
**Full research paper and figures, including visuals of the teeth studied, available now under embargo, upon request.**

Newswise — WASHINGTON—The search for a common ancestor linking modern humans with the Neanderthals who lived in Europe thousands of years ago has been a compelling subject for research. But a new study suggests the quest isn’t nearly complete.

Researchers, using quantitative methods focused on the shape of dental fossils, find that none of the usual suspects fits the expected profile of an ancestor of Neanderthals and modern humans. They also present evidence that the lines that led to Neanderthals and modern humans diverged nearly 1 million years ago, much earlier than studies based on molecular evidence have suggested.

The study, which will be published on Oct. 21 at 3 p.m. Eastern by the Proceedings of the National Academy of Sciences, was carried out by an international team of scholars from the George Washington University (GW), Konrad Lorenz Institute for Evolution and Cognition Research in Austria, Indiana University (IU) and Atapuerca Research Team in Spain.

“Our results call attention to the strong discrepancies between molecular and paleontological estimates of the divergence time between Neanderthals and modern humans," said Aida Gómez-Robles, lead author of the paper and a postdoctoral scientist at the Center for the Advanced Study of Hominid Paleobiology in the GW Columbian College of Arts and Sciences. “These discrepancies cannot be simply ignored, but they have to be somehow reconciled.”

P. David Polly, professor in the Department of Geological Sciences in the IU Bloomington College of Arts and Sciences, is a co-author of the study. Other co-authors are Spanish researchers José María Bermúdez de Castro, Juan-Luis Arsuaga and Eudald Carbonell, co-directors of the excavations at Atapuerca sites. The study resulted from a collaboration that developed when Dr. Gómez-Robles spent a semester at IU studying with Dr. Polly while she was a graduate student at the National Research Centre for Human Evolution and at the University of Granada, both in Spain. It also makes use of statistical methods developed by IU Bloomington biologist Emilia Martins.

The article, "No known hominin species matches the expected dental morphology of the last common ancestor of Neanderthals and modern humans," relies on fossils of approximately 1,200 molars and premolars from 13 species or types of hominins—humans and human relatives and ancestors. Fossils from the well-known Atapuerca sites have a crucial role in this research, accounting for more than 15 percent of the complete studied fossil collection.

The researchers use techniques of morphometric analysis and phylogenetic statistics to reconstruct the dental morphology of the last common ancestor of Neanderthals and modern humans. They conclude with high statistical confidence that none of the hominins usually proposed as a common ancestor, such as Homo heidelbergensis, H. erectus and H. antecessor, is a satisfactory match.

“None of the species that have been previously suggested as the last common ancestor of Neanderthals and modern humans has a dental morphology that is fully compatible with the expected morphology of this ancestor,” Dr. Gómez-Robles said.

The study also finds that the potential human ancestors discovered in Europe are morphologically closer to Neanderthals than to modern humans. This suggests the line leading to Neanderthals arose around 1 million years ago and the divergence of humans took place much earlier than previously thought. Other studies have placed the divergence around 350,000 years ago.

The researchers argue that quantitative and statistical methods provide a better way to settle debates about human origins than the descriptive analyses that have been used in the past. "Our primary aim," they wrote, "is to put questions about human evolution into a testable, quantitative framework and to offer an objective means to sort out apparently unsolvable debates about hominin phylogeny." They also suggest applying their methodology to study other body parts represented in the hominin fossil record.

What comes next? Answers to the ancestry question could come from studying hominin fossils from Africa, the researchers say. But the African fossil record from the era of interest is sparse.

“The study tells us that there are still new hominin finds waiting to be made,” Dr. Polly said. “Fossil finds from about 1 million years ago in Africa deserve close scrutiny as the possible ancestor of Neanderthals and modern humans.”

The Center for the Advanced Study of Hominid Paleobiology
The Center for the Advanced Study of Hominid Paleobiology is a research center at the George Washington University. CASHP’s mission is to undertake strategic research that addresses fundamental problems in human evolution that cross disciplinary boundaries, to act as a catalyst for interdisciplinary research programs involving scientists from other centers around the world and to promote interdisciplinary research through training and education.

The Columbian College of Arts and Sciences
Established in 1821 in the heart of the nation’s capital, the George Washington University Columbian College of Arts and Sciences is the largest of GW’s academic units. It encompasses the School of Media and Public Affairs, the Trachtenberg School of Public Policy and Public Administration and more than 40 departments and programs for undergraduate, graduate and professional studies. The Columbian College provides the foundation for GW’s commitment to the liberal arts and a broad education for all students. An internationally recognized faculty and active partnerships with prestigious research institutions place Columbian College at the forefront in advancing policy, enhancing culture and transforming lives through research and discovery.

The George Washington University
In the heart of the nation’s capital with additional programs in Virginia, the George Washington University was created by an Act of Congress in 1821. Today, GW is the largest institution of higher education in the District of Columbia. The university offers comprehensive programs of undergraduate and graduate liberal arts study, as well as degree programs in medicine, public health, law, engineering, education, business and international affairs. Each year, GW enrolls a diverse population of undergraduate, graduate and professional students from all 50 states, the District of Columbia and more than 130 countries.

Indiana University Bloomington
Indiana University Bloomington is the flagship residential, research-intensive campus of Indiana University. Its academic excellence is grounded in the humanities, arts and sciences and a range of highly ranked professional programs. Founded in 1820, the campus serves more than 42,000 undergraduate and graduate students pursuing degrees in more than 300 disciplines. Widely recognized for its global and international programs, outstanding technology and historic limestone campus, IU Bloomington serves as a global gateway for students and faculty members pursuing issues of worldwide significance.

- GW -



Shorter Sleep Duration and Poorer Sleep Quality Linked to Alzheimer's Disease Biomarker

AppId is over the quota AppId is over the quota 

Newswise — Poor sleep quality may impact Alzheimer’s disease onset and progression. This is according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health who examined the association between sleep variables and a biomarker for Alzheimer’s disease in older adults. The researchers found that reports of shorter sleep duration and poorer sleep quality were associated with a greater ß-Amyloid burden, a hallmark of the disease. The results are featured online in the October issue of JAMA Neurology.


“Our study found that among older adults, reports of shorter sleep duration and poorer sleep quality were associated with higher levels of ß-Amyloid measured by PET scans of the brain,” said Adam Spira, PhD, lead author of the study and an assistant professor with the Bloomberg School’s Department of Mental Health. “These results could have significant public health implications as Alzheimer’s disease is the most common cause of dementia, and approximately half of older adults have insomnia symptoms.”


Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills. According to the National Institutes of Health, as many as 5.1 million Americans may have the disease, with first symptoms appearing after age 60. Previous studies have linked disturbed sleep to cognitive impairment in older people.


In a cross-sectional study of adults from the neuro-imagining sub-study of the Baltimore Longitudinal Study of Aging with an average age of 76, the researchers examined the association between self-reported sleep variables and ß-Amyloid deposition. Study participants reported sleep that ranged from more than seven hours to no more than five hours. ß-Amyloid deposition was measured by the Pittsburgh compound B tracer and PET (positron emission tomography) scans of the brain. Reports of shorter sleep duration and lower sleep quality were both associated with greater ?ß buildup.


“These findings are important in part because sleep disturbances can be treated in older people. To the degree that poor sleep promotes the development of Alzheimer’s disease, treatments for poor sleep or efforts to maintain healthy sleep patterns may help prevent or slow the progression of Alzheimer disease,” said Spira. He added that the findings cannot demonstrate a causal link between poor sleep and Alzheimer’s disease, and that longitudinal studies with objective sleep measures are needed to further examine whether poor sleep contributes to or accelerates Alzheimer’s disease.


“Self-reported Sleep and ß-Amyloid Deposition in Community-Dwelling Older Adults,” was written by Adam P. Spira, Alyssa A. Gamaldo, Yang An, Mark N. Wu, Eleanor M. Simonsick, Murat Bilgel, Yun Zhou, Dean F. Wong, Luigi Ferrucci and Susan M. Resnick.


The research was supported in part by the National Institutes of Health and the Johns Hopkins School of Medicine Brain Science Institute. Dr. Spira is supported by Mentored Research Scientist Development Award (K01AG033195) from the National Institute on Aging.